secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280518
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025
--------------------------------------------------------------------------------

- Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.
- Cash and equivalents $48.6M as of Sep 30, 2025; company expects funding into 2028.
- Phase 3 PIVOT-PO trial of tebipenem HBr met primary endpoint; GSK to submit NDA to FDA in Q4 2025 with decision expected 2H 2026.
- SPR720 program for NTM pulmonary disease discontinued in Q3 2025 after Phase 2a/1 data review.
- R&D expenses fell to $8.6M from $26.9M due to lower PIVOT-PO and SPR720 costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/0001193125-25-280518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/d44321d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer